Palbociclib treatment in patients with HR+/HER2- advanced or metastatic breast cancer and visceral metastasis: A systematic literature review.

Breast · 2025 · PMC12683142 · PMID 40945169

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a significant trendno p-value reported

In both studies, palbociclib demonstrated significant trends in improved rwPFS versus ET alone in patients with visceral disease (lung and liver metastasis; HR range: 0.56−0.57), as well as in subgroups with only lung metastasis (HR range: 0.52−0.55); one showed a significant trend in improved rwPFS in patients with liver metastasis (HR: 0.57).

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.